remove_red_eye 524 Views
#Critical Care #Emergency Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health
Scientists are a step closer to finding the first effective treatments for the deadly Ebola hemorrhagic fever after two potential drugs showed survival rate of as much as 90% in a clinical trial in Congo.
Two experimental drugs - Regeneron’s REGN-EB3 and a monoclonal antibody called mAb114 - were both developed using antibodies harvested from survivors of Ebola infection. The treatments are now going to be offered to all patients in the Democratic Republic of Congo (DRC), according to U.S. National Institute of Allergy and Infectious Diseases… (Reuters, August 12, 2019)
To comment on this article,
create a free account.
Already registered?
Excellent : moving very fast ; Vaccine trail and now a step closer to finding the first effective mAb treatments showing survival rates of as much as 90 percent in the DRC clinical trial.